Guidant posts strong third quarter
This article was originally published in Clinica
Executive Summary
Cardiac rhythm management sales growth outpaced Guidant's total sales increase in the third quarter with a 20% rise to $119.3 million compared with last year. Strong demand for the Ventak PrxIII AICD implantable defibrillator and the new line of Vigor adaptive rate pacemakers in both the US and Europe led cardiac rhythm sales. The business sector contributed 46% of Guidant's third quarter sales which rose 8% to $234.1 million. Net income grew 8% to $28.0 million.